Recombinant Vaccines Worldwide Sales Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2021-2026

Report Code: HCR 58323 Report Format: PDF + Excel (Delivery in 48 Hrs)

Recombinant Vaccines Market Overview

The Recombinant Vaccines Market size was estimated at $12.68 billion in 2020, projected to grow at a CAGR of 13.7% during the forecast period 2021-2026. Initially, vaccinations were made on a trial-and-error basis, depending on pathogen attenuation or inactivation. Currently, the advent of advance technology such as Genetic engineering, genomics, and recombinant deoxyribonucleic acid (DNA) technology have revolutionized vaccine production thereby bringing safe and effective vaccines to market.

These vaccines are genetically manufactured and modified in the lab such that, the risk of infectious viral antigen is eradicated while ensuring vaccine efficacy and protection. The demand for recombinant vaccines is being driven by rising disease incidence and emerging technologies. The rise in diseases caused by bacteria or viruses, such as coronavirus, swine flu, malaria, HPV, and other diseases, has increased vaccination demand and led to the eradication of diseases like polio in a few countries. Moreover, with technological advancements, new vaccines are being developed that are more effective than traditional vaccines and have negative side effects are the major factor predicted to drive the market growth. However, factors such time taken to develop a vaccine along the high cost associated with each vaccine dose are restricting market development during the forecast period 2021-2026.

Recombinant Vaccines Market Report Coverage

The report: “Recombinant Vaccines Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Recombinant Vaccines Market.
By Type: Subunit and Live Attenuated.
By Route of Administration: Parenteral and Oral.
By Disease Indication: Covid-19, Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, Others.
By End Use: Hospitals and Clinics, Ambulatory Surgical Centers and others.
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Others), Asia-Pacific (China, Japan India, South Korea, Australia and Others), South America(Brazil, Argentina and others) and Rest of the World (Middle East and Africa).

Key Takeaways

  • Geographically, North America region held 42.2% of the total market share in 2020 owing to the rising geriatric population, growing disease incident and increasing health concerns.
  • Increasing incidence of infectious diseases such as HPV and Hepatitis B along with Covid-19 is a major driving force for the Recombinant Vaccines Market during the forecast period 2021-2026.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Recombinant Vaccines Market.

Recombinant Vaccines Market Segment Analysis- By Type

By Type, the global market can be classified into subunit and live attenuated. Recombinant subunit segment is projected to grow at a CAGR of 17.6% during the forecast period 2021-2026. The recombinant subunit vaccines only comprise of the recombinant protein but not the infectious virus, as a result it protects against viral diseases. The advent of recombinant subunit vaccines has provided manufacturers with new options for combating viral antigens. Owing to their efficacy in preventing HPV, Hepatitis B, Corvid 19 and other diseases, subunit vaccines market share is increasing in terms of sales all over the world.

Recombinant Vaccines Market Segment Analysis - By Disease Indication

Based on disease indication, the global market can be segmented into Covid-19, human papillomavirus, hepatitis B, rotavirus, herpes zoster, meningococcal B, and others. HPV vaccines in the disease indication segment account for the highest market share in 2020 and is projected to grow at a high CAGR of 16.3% during the forecast period 2021-2026. The dominance is due to higher vaccine sales worldwide as a result of increased demand and procurement speed. In addition, new HPV vaccine pipeline candidates are expected to boost market demand in the coming years.

However, Covid 19 vaccine is set to grow at the fastest CAGR due to the growing incidence and prevalence of the disease. Both COVISHIELD™ (manufactured by Serum Institute of India Pvt Ltd) and COVID-19 Vaccine AstraZeneca (manufactured by AstraZeneca) are ChAdOx1 nCoV- 19 Corona Virus Vaccines (Recombinant vaccine). Moreover, increased awareness among individuals about immunization benefits is further poised to increase the sales of the vaccines during the forecast period.

Recombinant Vaccines Market Segment Analysis - By Geography

Based on geography, North America dominated the Recombinant Vaccines Market with a region share of 42.2% in 2020 followed by Europe and APAC. Increased demand of advanced treatment, rising cases of infectious disease, and increasing health concerns are the major factor propelling the growth in this region. Moreover, the presence of large number of pharmaceutical and biotechnology company that invest heavily on the research along with the easy availability of technologically advanced molecular & genetic engineering instruments in this region is predicted to drive the market growth in this region. However, Asia Pacific is set to be the fastest growing region owing to the growing population and rising demand for a better healthcare structure during the forecast period 2021-2026.

Recombinant Vaccines Market - By Geography, 2020.


Recombinant Vaccines Market Drivers

Increasing incidence of infectious diseases

Increasing incidence of infectious diseases leading to Covid 19, Hepatitis-B and other diseases is a major factor driving the Recombinant Vaccines Market during the forecast period 2020-2025. According to the World Health Organization Covid-19 accounted for over a 100million cases worldwide and over 2.5 million deaths are directly, similarly, an estimated 30 million become newly infected each year and over 884,000 people die each year from hepatitis B and related complications such as liver cancer globally. The growing Covid-19 and Hepatitis cases and their will to immunize themselves is poised to propel the market.

Technological Advancement in Recombinant Vaccines Market 

Technological Advancements in the fields of recombinant DNA technology, genetic engineering, and proteomics, which is improving vaccine R&D is another major factor driving Recombinant Vaccines market during the forecast period 2020-2025. The technologies are further contributing to, increasing number of clinical trials and more investments by the major players. Moreover, due to its superior advantages for diverse and complex viral diseases such as COVID-19 and rotavirus big pharma companies are developing recombinant vaccines thereby contributing to market growth.

Recombinant Vaccines Market Challenge

High Cost of the Product

Despite the increased prevalence of chronic and infectious diseases, some factors are preventing product acceptance. The high cost associated with the per dose vaccine amount is one of them. Although international organizations are putting in their best efforts to provide millions of volume doses to every corner of the world, many areas of the country particularly the developing countries remain unvaccinated due to the high cost. For example Gardasil 9 costs about USD 227 per dose in the private sector, according to the CDC's revised vaccine price list for 2020. While Bexsero adult vaccine costs about USD 170. As a result, the high cost of vaccines makes it impossible for the middle class to afford vaccination, limiting adoption.

Recombinant Vaccines Market Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Recombinant Vaccines Market. Key companies of this market are GlaxoSmithKline, Sanofi, Novartis AG, Merck & Co. Inc, Pfizer Inc., Bharat Biotech, Bayer AG, Dynavax Technologies and Serum Institute of India Pvt Ltd.

Developments:

  • In December 2019, Merck received approval from the USFDA for a new vaccine. The ERVEBO is the first ever Ebola vaccine.
  • In May 2019, Sanofi received USFDA approval for Dengvaxia, a live attenuated dengue vaccine.

Relevant reports

Report Code: HCR 0397

Report Code: HCR 49911

For more Lifesciences and Healthcare Market reports, Please click here
1. Recombinant Vaccines Market Overview
    1.1 Definitions and Scope
2. Recombinant Vaccines Market Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trends By Type
    2.3 Key trends By Route of Administration
    2.4 Key trends By Disease Indication
    2.5 Key trends By End User
    2.6 Key trends By Geography
3. Recombinant Vaccines Market Landscape
    3.1 Product Benchmarking- Key Companies
    3.2 Financial Analysis- Key Companies
    3.3 Patent Analysis
    3.4 Pricing Analysis–Average Pricing
4. Recombinant Vaccines Market - Startup companies Scenario Premium Premium
    4.1 Key startup company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Application Analysis
        4.1.4 Venture Capital and Funding Scenario
5. Recombinant Vaccines Market - Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of successful ventures
6. Recombinant Vaccines Market Forces
    6.1 Market Drivers
    6.2 Market Constraints and Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining Power of Suppliers
        6.3.2 Bargaining Powers of Customers
        6.3.3 Threat of New Entrants
        6.3.4 Rivalry Among Existing Players
        6.3.5 Threat of Substitutes
7. Recombinant Vaccines Market Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Recombinant Vaccines Market – By Type
    8.1 Subunit
    8.2  Live Attenuated
9. Recombinant Vaccines Market – Route of Administration
    9.1 Parenteral
    9.2 Oral
10. Recombinant Vaccines Market – By Disease Indication
    10.1 Covid-19
    10.2 Human Papillomavirus
    10.3 Hepatitis B
    10.4 Rotavirus  
    10.5 Herpes Zoster
    10.6 Meningococcal B
    10.7 Others
11. Recombinant Vaccines Market – By End User
    11.1 Hospitals and Clinics
    11.2 Ambulatory Surgical Centers
    11.3 Others
12. Recombinant Vaccines Market - By Geography
    12.1 North America
        12.1.1 U.S
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K
        12.2.2 Germany
        12.2.3 France
        12.2.4 Spain
        12.2.5 Italy
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia Pacific
        12.3.1 India
        12.3.2 China
        12.3.3 Japan
        12.3.4 Australia
        12.3.5 South Korea
        12.3.6 Rest of Asia pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Recombinant Vaccines Market Entropy
14. Recombinant Vaccines Market - Industry / Segment Competition landscape Premium Premium
    14.1 Market Share Analysis
        14.1.1 Market Share by Country- Key companies
        14.1.2 Market Share by Region- Key companies
        14.1.3 Market Share at Global Level- Key companies
        14.1.4 Best Practices for Companies
15. Recombinant Vaccines Market - Key Company List by Country Premium Premium
16. Recombinant Vaccines Market Company Analysis (Company Revenue, Products, M&A, Developments)
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
 "*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Competition Analysis Market 2019-2024 ($M)
2.Global Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
3.Global Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)
4.Global Competition Analysis Market 2019-2024 (Volume/Units)
5.Global Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 (Volume/Units)
6.Global Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 (Volume/Units)
7.North America Competition Analysis Market 2019-2024 ($M)
8.North America Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
9.North America Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)
10.South America Competition Analysis Market 2019-2024 ($M)
11.South America Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
12.South America Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)
13.Europe Competition Analysis Market 2019-2024 ($M)
14.Europe Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
15.Europe Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)
16.APAC Competition Analysis Market 2019-2024 ($M)
17.APAC Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
18.APAC Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)
19.MENA Competition Analysis Market 2019-2024 ($M)
20.MENA Recombinant Vaccines Analysis and Forecast , By Product Type Market 2019-2024 ($M)
21.MENA Recombinant Vaccines Analysis and Forecast , By Distribution Channel Market 2019-2024 ($M)

LIST OF FIGURES

1.US Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
2.Canada Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
3.Mexico Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
4.Brazil Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
5.Argentina Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
6.Peru Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
7.Colombia Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
8.Chile Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
9.Rest of South America Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
10.UK Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
11.Germany Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
12.France Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
13.Italy Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
14.Spain Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
15.Rest of Europe Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
16.China Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
17.India Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
18.Japan Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
19.South Korea Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
20.South Africa Recombinant Vaccines Worldwide Sales Market Revenue, 2019-2024 ($M)
21.North America Recombinant Vaccines Worldwide Sales By Application
22.South America Recombinant Vaccines Worldwide Sales By Application
23.Europe Recombinant Vaccines Worldwide Sales By Application
24.APAC Recombinant Vaccines Worldwide Sales By Application
25.MENA Recombinant Vaccines Worldwide Sales By Application